Article
Biochemistry & Molecular Biology
Jiwon Yang, Jing Jiao, Kyle M. Draheim, Guoxiang Yang, Hongyuan Yang, Li-Chin Yao, Leonard D. Shultz, Dale L. Greiner, Deepa Rajagopal, Sandrine Vessillier, Curtis C. Maier, Sunish Mohanan, Danying Cai, Mingshan Cheng, Michael A. Brehm, James G. Keck
Summary: Immuno-oncology (IO)-based therapies have been successful in treating cancer, but may lead to severe adverse events like cytokine release syndrome (CRS). Currently, there is a lack of in vivo models to evaluate dose-response relationships and safety issues. This study tested an in vivo PBMC humanized mouse model using a specific T-cell engager (BiTE) to assess treatment efficacy and cytokine release. The results show that this model accurately predicts tumor control and cytokine release, and captures variability among donors. The PBMC humanized mouse model is a reliable platform to identify effective treatments and complications.
Article
Multidisciplinary Sciences
Emiko Desvaux, Antoine Hamon, Sandra Hubert, Cheima Boudjeniba, Bastien Chassagnol, Jack Swindle, Audrey Aussy, Laurence Laigle, Jessica Laplume, Perrine Soret, Pierre Jean-Francois, Isabelle Dupin-Roger, Mickael Guedj, Philippe Moingeon
Summary: This study utilized a computational repurposing approach to identify candidate therapeutic drugs to control progression towards severe airways inflammation during COVID-19. Analysis highlighted the potential of drugs such as dexamethasone, JAK2 inhibitors, estrogens, and inhibitors of alarmins or their receptors in preventing or slowing down the progression of severe COVID-19. The study also identified various drugs interacting with the aforementioned targets as potential treatments.
Review
Immunology
Tadamitsu Kishimoto
Summary: Tocilizumab, an anti-IL-6 receptor antibody, has been effective in treating chronic autoimmune inflammatory diseases and alleviating cytokine storms induced by CAR-T-cell therapy. It is also considered a potential therapeutic for serious cases of COVID-19 with cytokine release syndrome.
INTERNATIONAL IMMUNOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Alan H. Baik, Olalekan O. Oluwole, Douglas B. Johnson, Nina Shah, Joe-Elie Salem, Katy K. Tsai, Javid J. Moslehi
Summary: Immune-based therapies have transformed cancer treatments, but cardiovascular complications arising from these therapies present new challenges in cardio-oncology. Understanding the mechanisms of immune activation and associated cardiovascular toxicities is crucial for addressing the cardiovascular sequelae of immunotherapy.
CIRCULATION RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Eduardo Huarte, Michael T. Peel, Katherine Verbist, Brittany L. Fay, Rachel Bassett, Sabrin Albeituni, Kim E. Nichols, Paul A. Smith
Summary: Hyperinflammatory syndromes are characterized by severe inflammation, multiple organ dysfunction, and potential death. Oral ruxolitinib dosing effectively reduces the harmful consequences of immune overactivation in various hyperinflammatory models without causing broad immunosuppression.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Microbiology
Khalid Eljaaly, Husam Malibary, Shaimaa Alsulami, Muradi Albanji, Mazen Badawi, Jaffar A. Al-Tawfiq
Summary: This systematic review highlights the variability in CRS definitions and associated biomarker cutoff values in clinical trials on COVID-19 patients, emphasizing the need for a standardized definition of CRS.
Article
Chemistry, Multidisciplinary
Qian-Fang Meng, Rui Tian, Haiyi Long, Xianjia Wu, Jialin Lai, Olga Zharkova, Jiong-Wei Wang, Xiaoyuan Chen, Lang Rao
Summary: The COVID-19 pandemic, caused by SARS-CoV-2, has had a significant impact on the global economy and daily life. Some patients develop severe symptoms and complications due to a cytokine storm induced by the virus. While neutralizing antibodies targeting inflammatory cytokines show promise, challenges remain in their application, sparking interest in new biomaterials and nanotechnology for potential therapeutic advancements. Researchers are working towards developing novel treatments to effectively manage COVID-19 and other inflammatory diseases.
ADVANCED MATERIALS
(2021)
Article
Oncology
Nicki Panoskaltsis, Neil E. McCarthy, Stella C. Knight
Summary: TGN1412, a superagonist monoclonal antibody targeting CD28, caused cytokine storm in healthy volunteers, leading to anemia and granulocytic dysplasia which resolved over several months. The study provides insights into the changes in myelopoiesis and natural resolution in young healthy individuals following acute inflammation and cytokine storm.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Biotechnology & Applied Microbiology
Wenxia Luo, Olufola O. Ige, Tasnim H. Beacon, Ruey-Chyi Su, Shujun Huang, James R. Davie, Ted M. Lakowski
Summary: This article discusses antiviral treatments for SARS-CoV2 and treatment strategies for the CSS. It compares antivirals with in vitro activity against SARS-CoV2, SARS-CoV1 and MERS-CoV, and discusses medications that reduce the effects or expression of cytokines involved in the CSS. It also explores how some medications influence enzymes involved in epigenetic processes.
Article
Clinical Neurology
Umberto Pensato, Giulia Amore, Lorenzo Muccioli, Susanna Sammali, Francesca Rondelli, Rita Rinaldi, Roberto D'Angelo, Marianna Nicodemo, Susanna Mondini, Luisa Sambati, Gian Maria Asioli, Simone Rossi, Rossella Santoro, Lucia Cretella, Susy Ferrari, Luca Spinardi, Luca Faccioli, Stefano Fanti, Andrea Paccagnella, Elisabetta Pierucci, Beatrice Casadei, Cinzia Pellegrini, Pier Luigi Zinzani, Massimiliano Bonafe, Pietro Cortelli, Francesca Bonifazi, Maria Guarino
Summary: In this study, the clinical and instrumental features, incidence, risk factors, and prognosis of neurotoxicity in lymphoma patients who received CAR T-cell therapy were investigated. The results showed that 37% of patients developed neurotoxicity, characterized by encephalopathy and language disturbances. Baseline EEG abnormalities were important predictors for ICANS development. Neurological symptoms were completely resolved in all patients except for one who developed fatal cerebral edema, and no long-term neurotoxicity was observed.
JOURNAL OF NEUROLOGY
(2023)
Review
Medicine, Research & Experimental
Randy Q. Cron, Gaurav Goyal, W. Winn Chatham
Summary: Cytokine storm syndrome (CSS) is a frequently fatal hyperinflammatory condition that has gained attention during the ongoing coronavirus pandemic. It encompasses various hyperinflammatory disorders associated with multiorgan system failure, including familial hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Familial HLH is caused by genetic defects in the perforin pathway, while secondary HLH and MAS often involve NK cell dysfunction. Treatment for HLH involves targeting overactive lymphocytes and macrophages with etoposide and glucocorticoids, but more targeted and safer anticytokine approaches are becoming popular.
ANNUAL REVIEW OF MEDICINE
(2023)
Review
Immunology
Alice H. Grant, Armando Estrada III, Yoshira M. Ayala-Marin, America Y. Alvidrez-Camacho, Georgialina Rodriguez, Elisa Robles-Escajeda, Denisse A. Cadena-Medina, Alejandro C. Rodriguez, Robert A. Kirken
Summary: The SARS-CoV-2 virus has caused a global pandemic with devastating health and economic consequences. Immunologically, the effects of SARS-CoV-2 are traced back to a cytokine storm that activates the JAK-STAT pathway. Therapeutic strategies to combat the SARS-CoV-2 mediated storm focus on cell signaling and JAK inhibition.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Oncology
Nicki Panoskaltsis
Summary: Cytokine release syndrome (CRS) is a result of ongoing inflammation and tissue damage caused by massive pro-inflammatory cytokine release. CRS, triggered by COVID-19, has become a defining feature of severe cases, prompting the need for treatment approaches based on pathophysiology and cytokine storm.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Immunology
Nicole Paland, Antonina Pechkovsky, Miran Aswad, Haya Hamza, Tania Popov, Eduardo Shahar, Igal Louria-Hayon
Summary: COVID-19, caused by the novel RNA betacoronavirus SARS-CoV2, originated in Wuhan, China and has become a global pandemic with over 99 million cases and 2.1 million deaths. Severe cases require respiratory support due to respiratory failure, with most symptoms related to hyperinflammation. Treatments are still under clinical trials, highlighting the need for new anti-inflammatory therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
N. Broman, K. Rantasarkka, T. Feuth, M. Valtonen, M. Waris, U. Hohenthal, E. Rintala, A. Karlsson, H. Marttila, V. Peltola, T. Vuorinen, J. Oksi
Summary: IL-6 and CRP were found to be the strongest predictors of severity in hospitalized patients with COVID-19, showing significantly higher levels in patients eventually admitted to the ICU. No statistical differences were found in median levels of lymphocytes, D-dimer, or ferritin between the groups.
ANNALS OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
N. Lukan, O. Racz, I. Mocnejova, I. Tkac
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
(2008)
Article
Medicine, Research & Experimental
Norbert Lukan, Oliver Racz, Ema Paulovicova, Lveta Mocnejova, Jozefina Petrovicova
MEDICAL SCIENCE MONITOR
(2012)
Article
Allergy
Norbert Lukan, Peter Kolarcik, Veronika Benetinova, Tibor Varga
Article
Immunology
Jana Tulinska, Miroslava Lehotska Mikusova, Aurelia Liskova, Milena Busova, Vlasta Masanova, Iveta Uhnakova, Eva Rollerova, Radka Alacova, Zora Krivosikova, Ladislava Wsolova, Maria Dusinska, Mira Horvathova, Michaela Szabova, Norbert Lukan, Martina Stuchlikova, Daniel Kuba, Zbynek Vecera, Pavel Coufalik, Kamil Krumal, Lukas Alexa, Lucie Vrlikova, Marcela Buchtova, Jana Dumkova, Pavel Piler, Vojtech Thon, Pavel Mikuska
Summary: The ingestion of copper oxide nanoparticles (CuO NPs) can have negative effects on the immune system and antioxidant defense in mice, causing an increase in lymphocyte proliferation and secretion functions, impairment of granulocyte phagocytic activity, and decreased concentration of reduced glutathione.
FRONTIERS IN IMMUNOLOGY
(2022)